NO328070B1 - ECL-analyse for deteksjon av helikaseaktivitet, fremgangsmate for a identifisere et middel som modulerer helikaseaktivitet samt kit for ECL-deteksjon av helikaseaktivitet. - Google Patents

ECL-analyse for deteksjon av helikaseaktivitet, fremgangsmate for a identifisere et middel som modulerer helikaseaktivitet samt kit for ECL-deteksjon av helikaseaktivitet. Download PDF

Info

Publication number: NO328070B1
Authority: NO; Norway
Prior art keywords: helicase; nucleic acid; electrochemiluminescence; receptor; capping
Prior art date: 1999-10-05

Application number

NO20021585A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021585D0 (no

NO20021585L (no

Inventor

Litao Zang

Richard K Harrison

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-05

Filing date

2002-04-04

Publication date

2009-11-23

2002-04-04 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2002-04-04 Publication of NO20021585D0 publication Critical patent/NO20021585D0/no

2002-06-04 Publication of NO20021585L publication Critical patent/NO20021585L/no

2009-11-23 Publication of NO328070B1 publication Critical patent/NO328070B1/no

Links

108060004795 Methyltransferase Proteins 0.000 title claims abstract description 118
230000000694 effects Effects 0.000 title claims abstract description 42
238000000034 method Methods 0.000 title claims description 38
238000004458 analytical method Methods 0.000 title claims description 13
238000001514 detection method Methods 0.000 title description 7
238000003556 assay Methods 0.000 claims abstract description 53
239000003112 inhibitor Substances 0.000 claims abstract description 12
102000039446 nucleic acids Human genes 0.000 claims description 106
108020004707 nucleic acids Proteins 0.000 claims description 106
150000007523 nucleic acids Chemical class 0.000 claims description 106
230000000295 complement effect Effects 0.000 claims description 28
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 24
239000003446 ligand Substances 0.000 claims description 24
108090001008 Avidin Proteins 0.000 claims description 12
229960002685 biotin Drugs 0.000 claims description 12
235000020958 biotin Nutrition 0.000 claims description 12
239000011616 biotin Substances 0.000 claims description 12
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 10
239000003550 marker Substances 0.000 claims description 9
230000001717 pathogenic effect Effects 0.000 claims description 9
239000013522 chelant Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
230000001580 bacterial effect Effects 0.000 claims description 7
229910052707 ruthenium Inorganic materials 0.000 claims description 7
230000002538 fungal effect Effects 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
230000003612 virological effect Effects 0.000 claims description 6
238000001378 electrochemiluminescence detection Methods 0.000 claims description 5
244000045947 parasite Species 0.000 claims description 3
230000005518 electrochemistry Effects 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
201000010099 disease Diseases 0.000 abstract description 7
238000013537 high throughput screening Methods 0.000 abstract description 4
239000002831 pharmacologic agent Substances 0.000 abstract description 4
108020004414 DNA Proteins 0.000 description 69
108091034117 Oligonucleotide Proteins 0.000 description 37
239000000758 substrate Substances 0.000 description 25
102000053602 DNA Human genes 0.000 description 23
108010006296 DnaB Helicases Proteins 0.000 description 20
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
108020003175 receptors Proteins 0.000 description 14
238000002821 scintillation proximity assay Methods 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
239000002773 nucleotide Substances 0.000 description 11
239000000523 sample Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
238000009396 hybridization Methods 0.000 description 9
241000588724 Escherichia coli Species 0.000 description 8
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
108020004682 Single-Stranded DNA Proteins 0.000 description 8
239000011324 bead Substances 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
238000010791 quenching Methods 0.000 description 7
230000000171 quenching effect Effects 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 6
230000006870 function Effects 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
238000011084 recovery Methods 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
108090000133 DNA helicases Proteins 0.000 description 5
102000003844 DNA helicases Human genes 0.000 description 5
108010090804 Streptavidin Proteins 0.000 description 5
239000012634 fragment Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
238000012216 screening Methods 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
101710176276 SSB protein Proteins 0.000 description 4
101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 4
241000700605 Viruses Species 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
230000027455 binding Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 3
102000052510 DNA-Binding Proteins Human genes 0.000 description 3
241000701533 Escherichia virus T4 Species 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
244000052769 pathogen Species 0.000 description 3
-1 phosphate ester Chemical class 0.000 description 3
150000008300 phosphoramidites Chemical class 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
101710116602 DNA-Binding protein G5P Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
229910052693 Europium Inorganic materials 0.000 description 2
108010046914 Exodeoxyribonuclease V Proteins 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
101710162453 Replication factor A Proteins 0.000 description 2
101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000007877 drug screening Methods 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000002372 labelling Methods 0.000 description 2
244000144972 livestock Species 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
239000010948 rhodium Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
150000007970 thio esters Chemical class 0.000 description 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
241000712891 Arenavirus Species 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000606660 Bartonella Species 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000589968 Borrelia Species 0.000 description 1
241000589562 Brucella Species 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241001112696 Clostridia Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241001445332 Coxiella <snail> Species 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000224431 Entamoeba Species 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000224466 Giardia Species 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
241000589902 Leptospira Species 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000187654 Nocardia Species 0.000 description 1
241000713112 Orthobunyavirus Species 0.000 description 1
241000606860 Pasteurella Species 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
241000589970 Spirochaetales Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
101150104425 T4 gene Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
241000589886 Treponema Species 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
241000202898 Ureaplasma Species 0.000 description 1
241000607598 Vibrio Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000005401 electroluminescence Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000012010 growth Effects 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002523 lectin Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
239000002901 radioactive waste Substances 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000001776 time-resolved fluorescence quenching Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
239000013598 vector Substances 0.000 description 1
238000012795 verification Methods 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000003260 vortexing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Luminescent Compositions (AREA)
Investigating Or Analysing Biological Materials (AREA)
Battery Electrode And Active Subsutance (AREA)
Polyurethanes Or Polyureas (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20021585A 1999-10-05 2002-04-04 ECL-analyse for deteksjon av helikaseaktivitet, fremgangsmate for a identifisere et middel som modulerer helikaseaktivitet samt kit for ECL-deteksjon av helikaseaktivitet. NO328070B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/410,960 US6448004B1 (en)	1999-10-05	1999-10-05	Electrochemiluminescence helicase assay
PCT/US2000/027453 WO2001025487A2 (en)	1999-10-05	2000-10-05	Electrochemiluminescence helicase assay

Publications (3)

Publication Number	Publication Date
NO20021585D0 NO20021585D0 (no)	2002-04-04
NO20021585L NO20021585L (no)	2002-06-04
NO328070B1 true NO328070B1 (no)	2009-11-23

Family

ID=23626978

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021585A NO328070B1 (no)	1999-10-05	2002-04-04	ECL-analyse for deteksjon av helikaseaktivitet, fremgangsmate for a identifisere et middel som modulerer helikaseaktivitet samt kit for ECL-deteksjon av helikaseaktivitet.

Country Status (19)

Country	Link
US (2)	US6448004B1 (de)
EP (1)	EP1222311B1 (de)
JP (1)	JP2003511660A (de)
KR (1)	KR100729550B1 (de)
AT (1)	ATE334227T1 (de)
AU (1)	AU783653B2 (de)
BR (1)	BR0014507A (de)
CA (1)	CA2386642C (de)
DE (1)	DE60029607T2 (de)
DK (1)	DK1222311T3 (de)
ES (1)	ES2265989T3 (de)
HK (1)	HK1046934B (de)
IL (2)	IL148941A0 (de)
MX (1)	MXPA02003385A (de)
NO (1)	NO328070B1 (de)
NZ (1)	NZ518010A (de)
PT (1)	PT1222311E (de)
WO (1)	WO2001025487A2 (de)
ZA (1)	ZA200202331B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6448004B1 (en) *	1999-10-05	2002-09-10	Aventis Pharmaceuticals Inc.	Electrochemiluminescence helicase assay
US20050136439A1 (en) *	2003-09-12	2005-06-23	North Carolina State University	Novel methods of inorganic compound discovery and synthesis
EP1687406B1 (de) *	2003-11-10	2010-01-27	Geneohm Sciences, Inc.	Nukleinsäurenachweisverfahren mit erhöhter empfindlichkeit
ES2371664T3 (es) *	2005-06-03	2012-01-09	Beacon Biotechnology Llc	Ensayo de ácidos nucleicos de proximidad de quimioluminiscencia.
US20100092960A1 (en) *	2008-07-25	2010-04-15	Pacific Biosciences Of California, Inc.	Helicase-assisted sequencing with molecular beacons
WO2011150227A1 (en) *	2010-05-26	2011-12-01	Qiagen Gaithersburg, Inc.	Quantitative helicase assay

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4568649A (en)	1983-02-22	1986-02-04	Immunex Corporation	Immediate ligand detection assay
ZA929319B (en)	1991-12-11	1993-05-24	Igen Inc	Method for exponential amplification of nucleic acid by a single unpaired primer.
CA2172248C (en)	1993-09-22	2003-12-30	John Kenten	Self-sustained sequence replication electrochemiluminescent nucleic acid assay
US5747247A (en)	1994-07-25	1998-05-05	The Regents Of The University Of California	Spectroscopic helicase assay
US5705344A (en)	1996-03-14	1998-01-06	Tularik, Inc.	High-throughput screening assay for inhibitors of nucleic acid helicases
US6448004B1 (en) *	1999-10-05	2002-09-10	Aventis Pharmaceuticals Inc.	Electrochemiluminescence helicase assay

1999
- 1999-10-05 US US09/410,960 patent/US6448004B1/en not_active Expired - Lifetime
2000
- 2000-10-05 NZ NZ518010A patent/NZ518010A/en unknown
- 2000-10-05 IL IL14894100A patent/IL148941A0/xx active IP Right Grant
- 2000-10-05 ES ES00968716T patent/ES2265989T3/es not_active Expired - Lifetime
- 2000-10-05 KR KR1020027004278A patent/KR100729550B1/ko not_active Expired - Fee Related
- 2000-10-05 JP JP2001528637A patent/JP2003511660A/ja active Pending
- 2000-10-05 WO PCT/US2000/027453 patent/WO2001025487A2/en not_active Ceased
- 2000-10-05 MX MXPA02003385A patent/MXPA02003385A/es active IP Right Grant
- 2000-10-05 DE DE60029607T patent/DE60029607T2/de not_active Expired - Lifetime
- 2000-10-05 CA CA002386642A patent/CA2386642C/en not_active Expired - Fee Related
- 2000-10-05 PT PT00968716T patent/PT1222311E/pt unknown
- 2000-10-05 DK DK00968716T patent/DK1222311T3/da active
- 2000-10-05 HK HK02108268.6A patent/HK1046934B/en not_active IP Right Cessation
- 2000-10-05 AU AU78589/00A patent/AU783653B2/en not_active Ceased
- 2000-10-05 AT AT00968716T patent/ATE334227T1/de not_active IP Right Cessation
- 2000-10-05 EP EP00968716A patent/EP1222311B1/de not_active Expired - Lifetime
- 2000-10-05 BR BR0014507-6A patent/BR0014507A/pt not_active Application Discontinuation
2002
- 2002-03-22 ZA ZA200202331A patent/ZA200202331B/en unknown
- 2002-03-31 IL IL148941A patent/IL148941A/en not_active IP Right Cessation
- 2002-04-04 NO NO20021585A patent/NO328070B1/no not_active IP Right Cessation
- 2002-06-28 US US10/187,212 patent/US7041451B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO20021585D0 (no)	2002-04-04
AU7858900A (en)	2001-05-10
HK1046934B (en)	2006-10-20
NO20021585L (no)	2002-06-04
US20020127549A1 (en)	2002-09-12
DK1222311T3 (da)	2006-11-06
PT1222311E (pt)	2006-10-31
US7041451B2 (en)	2006-05-09
WO2001025487A3 (en)	2001-12-13
ZA200202331B (en)	2003-08-27
AU783653B2 (en)	2005-11-17
KR20020059445A (ko)	2002-07-12
IL148941A (en)	2007-08-19
IL148941A0 (en)	2002-09-12
WO2001025487A2 (en)	2001-04-12
CA2386642A1 (en)	2001-04-12
KR100729550B1 (ko)	2007-06-19
ES2265989T3 (es)	2007-03-01
EP1222311A2 (de)	2002-07-17
DE60029607D1 (de)	2006-09-07
EP1222311B1 (de)	2006-07-26
BR0014507A (pt)	2002-06-11
JP2003511660A (ja)	2003-03-25
HK1046934A1 (en)	2003-01-30
US6448004B1 (en)	2002-09-10
DE60029607T2 (de)	2007-07-26
ATE334227T1 (de)	2006-08-15
NZ518010A (en)	2003-05-30
US20030032041A1 (en)	2003-02-13
CA2386642C (en)	2007-05-29
MXPA02003385A (es)	2004-09-10

Legal Events

Date	Code	Title	Description
2011-05-30	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
CN103946397B (zh)	2021-03-16	用于通用实时多重分析检测的双功能寡核苷酸探针
US9994894B2 (en)	2018-06-12	Method and components for detecting nucleic acid chains
WO2012022755A1 (en)	2012-02-23	Helicase dependent isothermal amplification using nicking enzymes
KR20070011354A (ko)	2007-01-24	취약 ｘ염색체 증후군과 같은 ｓｔｒｐ의 검출 방법
US12559793B2 (en)	2026-02-24	Looped primer and loop-de-loop method for detecting target nucleic acid
JP2022145606A (ja)	2022-10-04	核酸の正確な並行定量のための高感度な方法
JPWO2012077819A1 (ja)	2014-05-22	標的核酸の検出方法及びキット
EP0763133A4 (de)	1999-02-10	Methode zur detektion einer gezielten nukleinsäure
NO328070B1 (no)	2009-11-23	ECL-analyse for deteksjon av helikaseaktivitet, fremgangsmate for a identifisere et middel som modulerer helikaseaktivitet samt kit for ECL-deteksjon av helikaseaktivitet.
US20080090238A1 (en)	2008-04-17	Increased sensitivity of proximity ligation assays
EP3682033B1 (de)	2025-12-03	Sequenzierung von nukleinsäuremolekülen
US20180245140A1 (en)	2018-08-30	Kit and method for detecting single nucleotide polymorphism
JP2017163920A (ja)	2017-09-21	核酸増幅法
Ouedraogo et al.	2024	Colorimetric detection of single-nucleotide mutations based on rolling circle amplification and G-quadruplex-based DNAzyme
JP2020096592A (ja)	2020-06-25	亜硝酸酸化細菌に結合する核酸分子並びに核酸分子を用いた亜硝酸酸化細菌の検出方法、検出キット及び検出試薬
JP2024541674A (ja)	2024-11-08	核酸の検出および定量
KR100318222B1 (ko)	2002-06-24	표적핵산의검출방법
WO2006051991A1 (ja)	2006-05-18	核酸の増幅および検出方法